全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Delineation of 2q32q35 Deletion Phenotypes: Two Apparent “Proximal” and “Distal” Syndromes

DOI: 10.1155/2013/823451

Full-Text   Cite this paper   Add to My Lib

Abstract:

We report on three patients with interstitial deletions of the long arm of chromosome 2 involving bands 2q32.1–q35. They presented with wide-ranging phenotypic variation including facial dysmorphisms, cleft palate, learning difficulties, behavioural issues and severe heart defects. Microarray analysis confirmed an 8.6?Mb deletion in patients 1 and 2 and a 24.7?Mb deletion in patient 3. We discuss the genes involved in the deleted regions including MYO1B, GLS, FRZB, SATB2, and CPS1 and compare the phenotype with those reported in the literature. Taken together, these data suggest that there is a spectrum of disease severity such that patients with deletions encompassing the region of 2q32.1q32.2, which includes the FRZB gene, show an apparently milder phenotype compared to those that lie further distal in 2q32.3q35 that encompasses the SATB2 gene. 1. Introduction Interstitial deletions of the long arm of chromosome 2 involving the 2q31q33 region are responsible for a number of clinical features, including facial dysmorphism, developmental delay, failure to thrive, mental retardation, and behavioural disturbances [1, 2]. There have been approximately 40 patients described in the literature, but a significant number of these cases are not highly resolved, so genotype-phenotype correlations have been difficult to make. More recently, molecular karyotyping has allowed high-resolution characterisation of these deletions. Van Buggenhout et al. [3] have described four independent patients and reported a recognisable pattern of clinical anomalies. Rifai et al. [4] and Cocchella et al. [1] reported two further cases, with the latter refining a critical region for the syndrome and identifying candidate genes to explain the phenotype [5]. The study described here reports on three further cases involving the interstitial region 2q32q35. Patient 1 and her mother, patient 2, carry an 8.6?Mb heterozygous deletion of region 2q32.1q32.3. Patient 3 carries a 24.7?Mb heterozygous deletion involving the region 2q32.2q35. 2. Clinical Report 2.1. Patient 1 The proband (patient 1) was the first child to a nonconsanguineous couple. The antenatal ultrasound scan was normal at 21-week gestation. At 29 + 4 weeks, a clot was seen in the ductus arteriosus, resulting in poor right ventricular function and hydrops fetalis; no structural malformations were observed. An amniocentesis was performed and showed a normal male karyotype. The baby was delivered by emergency caesarean section at 29 + 4 weeks. Despite attempts at resuscitation, the baby died an hour after delivery. Postmortem

References

[1]  A. Cocchella, M. Malacarne, F. Forzano et al., “The refinement of the critical region for the 2q31.2q32.3 deletion syndrome indicates candidate genes for mental retardation and speech impairment,” The American Journal of Medical Genetics B, vol. 153, no. 7, pp. 1342–1346, 2010.
[2]  J. C. Ramer, P. N. Mowrey, D. B. Robins, S. Ligato, J. Towfighi, and R. L. Ladda, “Five children with del (2)(q31q33) and one individual with dup (2)(q31q33) from a single family: review of brain, cardiac, and limb malformations,” The American Journal of Medical Genetics, vol. 37, no. 3, pp. 392–400, 1990.
[3]  G. Van Buggenhout, C. Van Ravenswaaij-Arts, N. Mc Maas et al., “The del(2)(q32.2q33) deletion syndrome defined by clinical and molecular characterization of four patients,” European Journal of Medical Genetics, vol. 48, no. 3, pp. 276–289, 2005.
[4]  L. Rifai, M. Port-Lis, A. Tabet et al., “Ectodermal dysplasia-like syndrome with mental retardation due to contiguous gene deletion: further clinical and molecular delineation of del(2q32) syndrome,” The American Journal of Medical Genetics A, vol. 152, no. 1, pp. 111–117, 2010.
[5]  S. I. Ferreira, E. Matoso, M. Venancio, J. Saraiva, J. B. Melo, and I. M. Carreira, “Critical region in 2q31.2q32.3 deletion syndrome: reports of two phenotypically distinct patients, one with an additional deletion in Alagille syndrome region,” Molecular Cytogenetics, vol. 5, no. 1, article 25, 2012.
[6]  M. A. Mencarelli, R. Caselli, C. Pescucci et al., “Clinical and molecular characterization of a patient with a 2q31.2-32.3 deletion identified by array-CGH,” The American Journal of Medical Genetics A, vol. 143, no. 8, pp. 858–865, 2007.
[7]  M. Balasubramanian, K. Smith, L. Basel-Vanagaite et al., “Case series: 2q33.1 microdeletion syndrome-further delineation of the phenotype,” Journal of Medical Genetics, vol. 48, no. 5, pp. 290–298, 2011.
[8]  P. Prontera, L. Bernardini, G. Stangoni et al., “2q31.2q32.3 deletion syndrome: report of an adult patient,” The American Journal of Medical Genetics A, vol. 149, no. 4, pp. 706–712, 2009.
[9]  S. B. Prusiner, “Disorders of glutamate metabolism and neurological dysfunction,” Annual Review of Medicine, vol. 32, pp. 521–542, 1981.
[10]  J. E. Lee, “NeuroD and neurogenesis,” Developmental Neuroscience, vol. 19, no. 1, pp. 27–32, 1997.
[11]  F. S. Alkuraya, I. Saadi, J. J. Lund, A. Turbe-Doan, C. C. Morton, and R. L. Maas, “SUM01 haploinsufficiency leads to cleft lip and palate,” Science, vol. 313, no. 5794, p. 1751, 2006.
[12]  O. Britanova, M. J. Depew, M. Schwark et al., “Satb2 haploinsufficiency phenocopies 2q32-q33 deletions, whereas loss suggests a fundamental role in the coordination of jaw development,” The American Journal of Human Genetics, vol. 79, no. 4, pp. 668–678, 2006.
[13]  B. Hoang, M. Moos Jr., S. Vukicevic, and F. P. Luyten, “Primary structure and tissue distribution of FRZB, a novel protein related to Drosophila frizzled, suggest a role in skeletal morphogenesis,” The Journal of Biological Chemistry, vol. 271, no. 42, pp. 26131–26137, 1996.
[14]  A. C. McPherron, A. M. Lawler, and S. Lee, “Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member,” Nature, vol. 387, no. 6628, pp. 83–90, 1997.
[15]  M. Schuelke, K. R. Wagner, L. E. Stolz et al., “Myostatin mutation associated with gross muscle hypertrophy in a child,” The New England Journal of Medicine, vol. 350, no. 26, pp. 2682–2688, 2004.
[16]  F. Malfait, P. Coucke, S. Symoens, B. Loeys, L. Nuytinck, and A. de Paepe, “The molecular basis of classic Ehlers-Danlos syndrome: a comprehensive study of biochemical and molecular findings in 48 unrelated patients,” Human Mutation, vol. 25, no. 1, pp. 28–37, 2005.
[17]  P. Narcisi, A. J. Richards, S. D. Ferguson, and F. M. Pope, “A family with Ehlers-Danlos syndrome type IlI/articular hypermobility syndrome has a glycine 637 to serine substitution in type III collagen,” Human Molecular Genetics, vol. 3, no. 9, pp. 1617–1620, 1994.
[18]  M. Pepin, U. Schwarze, A. Superti-Furga, and P. H. Byers, “Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type,” The New England Journal of Medicine, vol. 342, no. 10, pp. 673–680, 2000.
[19]  U. Schwarze, W. I. Schievink, E. Petty et al., “Haploinsufficiency for one COL3A1 allele of type III procollagen results in a phenotype similar to the vascular form of Ehlers-Danlos syndrome, Ehlers-Danlos syndrome type IV,” The American Journal of Human Genetics, vol. 69, no. 5, pp. 989–1001, 2001.
[20]  J. Urquhart, G. C. M. Black, and J. Clayton-Smith, “4.5?Mb microdeletion in chromosome band 2q33.1 associated with learning disability and cleft palate,” European Journal of Medical Genetics, vol. 52, no. 6, pp. 454–457, 2009.
[21]  T. J. de Ravel, I. Balikova, P. Thiry, J. R. Vermeesch, and J. Frijns, “Another patient with a de novo deletion further delineates the 2q33.1 microdeletion syndrome,” European Journal of Medical Genetics, vol. 52, no. 2-3, pp. 120–122, 2009.
[22]  M. L. Loscalzo, R. L. Galczynski, A. Hamosh, M. Summar, J. M. Chinsky, and G. H. Thomas, “Interstitial deletion of chromosome 2q32-34 associated with multiple congenital anomalies and a urea cycle defect (CPS I deficieney),” The American Journal of Medical Genetics, vol. 128, no. 3, pp. 311–315, 2004.
[23]  D. R. FitzPatrick, I. M. Carr, L. McLaren et al., “Identification of SATB2 as the cleft palate gene on 2q32-q33,” Human Molecular Genetics, vol. 12, no. 19, pp. 2491–2501, 2003.
[24]  J. A. Rosenfeld, B. C. Ballif, A. Lucas et al., “Small deletions of SATB2 cause some of the clinical features of the 2q33.1 microdeletion syndrome,” PloS one, vol. 4, no. 8, Article ID e6568, 2009.
[25]  D. L. Pearson, S. Dawling, W. F. Walsh et al., “Neonatal pulmonary hypertension: urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function,” The New England Journal of Medicine, vol. 344, no. 24, pp. 1832–1838, 2001.
[26]  J. Graw, “Genetics of crystallins: cataract and beyond,” Experimental Eye Research, vol. 88, no. 2, pp. 173–189, 2009.
[27]  L. Li, B. Chang, C. Cheng et al., “Dense nuclear cataract caused by the γB-crystallin S11R point mutation,” Investigative Ophthalmology and Visual Science, vol. 49, no. 1, pp. 304–309, 2008.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413